Neuros Australia raises A$18M Series B for sleep apnoea DBS pivotal trial
Summary
Brisbane-based Neuros Australia closed an A$18M Series B led by Brandon Capital Partners with OneVentures and CSIRO's Main Sequence Ventures, to fund the pivotal trial of their Dreamforge closed-loop hypoglossal nerve stimulator for obstructive sleep apnoea. The trial will enroll 160 patients across 12 centers in Australia, New Zealand, and Singapore.
Why it matters
A$18M for a 160-patient pivotal trial across 12 Asia-Pacific centers is a well-sized round for this phase. The Asia-Pacific focus is strategically smart — the highest sleep apnoea prevalence globally is in Southeast Asia, and regulatory approvals from TGA (Australia) and HSA (Singapore) create a large initial market without competing against Inspire Medical's established US presence.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial